Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce the appointment of Dr. Gabrielle M Siegers, MA, Ph.D., as the Head of R&D based out of the Company’s lab in Edmonton.

Helix Biopharma Corp. Announces Conclusion of Funding Agreement with Lind Global Macro Fund LP

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce that it has completed the buyback of the outstanding amount of the convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, …

Helix Biopharma Corp. Announces Scientific Collaboration with University Hospital Tuebingen

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce that it has entered into a two-year scientific collaboration agreement (“Agreement”) with University Hospital Tuebingen (Germany) to assess the therapeutic response of L-DOS47 …

Helix Biopharma Corp Announces Fiscal 2022 Third Quarter Results

(Toronto Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 third quarter results for the period ending April 30, 2022.

Helix Biopharma Corp. Announces Closure of Early Warrant Exercise Incentive Program | Raises Aggregate $3.21 Million

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that it has successfully closed its Early Warrant Exercise Incentive Program (the “Incentive Program”) and Extension of Warrant Exercise Period (“Warrant Extension”), previously announced …

Helix Biopharma Corp. Announces Appointment of New Chief Financial Officer

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce the appointment of Mr. Hatem Kawar as the Company’s Chief Financial Officer effective immediately. The appointment of Mr. Kawar is key in positioning HBP …

Helix Biopharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per …

Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company’), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that Artur Gabor has been appointed as the Company’s Chief Executive Officer with immediate effect.

Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend its previously announced Early Warrant Exercise Incentive Program (the …

Helix Announces Board Resignation

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a dinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect.